Status:
RECRUITING
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Lupus Erythematosus, Systemic
Lupus Nephritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematos...
Eligibility Criteria
Inclusion
- Key
- Men and women with SLE, aged \>= 18 years and =\< 75 years at screening, fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE at screening.
- Participant must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of \>= 1:80 (on HEp-2 cells or an equivalent positive test), or anti-dsDNA (above the ULN); or anti-Sm (above the ULN) as determined by a central laboratory.
- Active lupus nephritis without signs of significant chronicity or active systemic lupus erythematosus
- SLEDAI-2K Criteria at screening: SLEDAI-2K score \>= 6 points (Gladman et al 2002, Touma et al 2011), excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome".
- Inadequate response at screening to at least two therapies
- Key
Exclusion
- Any acute, severe lupus related-flare at screening that needs immediate treatment other than pulse GCs and/or makes the immunosuppressive washout impossible and, thus, makes the participant ineligible for CD19 CAR-T therapy
- Inadequate organ function during screening and prior to randomization
- History or current diagnosis of ECG or cardiac abnormalities indicating significant risk of safety for participants prior to randomization
- Human immunodeficiency virus (HIV) positivity at screening.
- Acute or chronic infection with hepatitis B (HBV) or hepatitis C (HCV) at screening.
- Grade 2 or higher thromboembolic event in the past 4 weeks prior to screening.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
September 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 6 2032
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT06581198
Start Date
September 4 2024
End Date
February 6 2032
Last Update
December 22 2025
Active Locations (87)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Alabama
Birmingham, Alabama, United States, 35294
2
Loma Linda University
San Bernardino, California, United States, 92408
3
UCSF
San Francisco, California, United States, 94115
4
UCSF
San Francisco, California, United States, 94115